Both Semaglutide GLP-1 (Ozempic and Wegovy) and Tirzepatide (Mounjaro) were originally created for use in treatment for those with type 2 diabetes to help manage the condition but were quickly realized to have fantastic weight loss benefits as well, which is why they are both so frequently used as part of weight loss treatments
Despite their benefits, access to GLP-1 medications remains inequitable
Injectable Wegovy (2.4 mg weekly) In the STEP 1 clinical trial, people taking injectable Wegovy lost an average of about 14.9% of their body weight over 68 weeks , combined with lifestyle changes
The exact amount varies based on the severity of the side effects and the impact on the individuals life
It can also help to reduce cravings, as people are less likely to snack if they feel satisfied or comfortably full
If you qualify following an evaluation, Klinic can help you find affordable weight loss care today